RF10 | PMON218 Direct Costs of Mental Health Disorders in PCOS: Systematic Review and Meta-Analysis

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most prevalent endocrine abnormality of reproductive-aged women today, affecting one in seven reproductive-aged women worldwide, and represents a significant financial burden to our health care. Women with PCOS have an increased risk for developing mental health (MH) disorders, in part due to biochemical changes, constant concerns regarding physical appearance, and social stigma from hirsutism, obesity, and infertility. OBJECTIVE: To determine the excess economic burden associated with MH disorders in women with PCOS. METHOD: Followed PRISMA reporting guidelines for systematic review, we searched PubMed, Web of Science, EBSCO, Medline, Scopus, and PsycINFO through July 16, 2021 for studies on MH disorders in PCOS. Excluded were studies not in humans, without controls, without original data, or not peer-reviewed. As anxiety, depression, and eating disorders were by far the most common MH disorders assessed by the studies, we performed our meta-analysis on these disorders. Meta-analyses were performed using the DerSimonian-Laird random-effects model (DerSimonian and Laird 1986) to compute pooled estimates of odds ratios (OR) for the associations between PCOS and anxiety, depression, and eating disorders. Study-specific and overall estimates using the log-odds scale were presented using forest plots. Between-study heterogeneity was evaluated using the I2 statistic. We then calculated the excess direct costs of these MH in U.S. dollars (USD) for women suffering from PCOS. RESULT: ​​We screened 72 articles by title/abstract, assessed 37 articles in full-text, and included 24 articles. Pooled ORs were 1.65 (95% CI: 1.15-2.38) for anxiety, 2.20 (95% CI: 1.69-2.86) for depression, and 2.53 (95% CI: 1.14-2.07) for eating disorders, for PCOS relative to controls. In the U.S., the additional direct healthcare costs associated with MH disorders in PCOS were estimated to be $3.075 billion/yr., $2.280 billion/yr., and $0.714 billion/yr. in 2021 USD for depression, anxiety, and eating disorders, respectively. Taken together, the additional direct healthcare costs associated with these MH disorders in PCOS was estimated to be $6.069 billion/yr. in 2021 USD. CONCLUSION: This work is the first to estimate the excess direct healthcare costs of MH disorders associated with PCOS. Overall, the direct healthcare costs for the most common MH disorders in PCOS, namely depression, anxiety, and eating disorders, exceeded $6 billion in 2021 USD for the U.S. population alone. Taken together with our prior work, these data suggest that the healthcare-related economic burden of PCOS exceeds $14 billion yearly, considering the costs of diagnosis, and MH, reproductive, vascular, and metabolic disorders (but not indirect and intangible costs). As PCOS is a global disorder with much the same prevalence across the world, the excess economic burden attributable to PCOS globally is enormous, mandating that the scientific and policy community increase its focus on this important disorder. Presentation: Saturday, June 11, 2022 1:36 p.m. - 1:41 p.m., Monday, June 13, 2022 12:30 p.m. - 2:30 p.m.

Improving emotional and psychosexual well-being screening in women living with polycystic ovary syndrome: experiences from the United Kingdom and India

“…In the UK, the National Institute of Health and Care Excellence (NICE) guideline recommends that healthcare professionals ‘ask about emotional wellbeing and manage as appropriate’ in those affected with PCOS ( 9 ), again, without any specific advice on how to screen or manage the same. The direct healthcare costs associated with depression, anxiety, and eating disorders in PCOS were estimated to be $6.069 billion per year in 2021 in the United States of America (USA) ( 10 ). The overall disease burden on the National Health Service (NHS) from PCOS was estimated to be >£7 billion in 2014 ( 11 ).…”